NCT07728097尚未招募4 期
A Phase 3b/4, Interventional, Prospective, Multicenter, Open-Label Study Evaluating the Effectiveness of a Gradual Titration Regimen to Optimize CBD-OS as Add-On Therapy in Adults With Lennox-Gastaut Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequency
研究概览
简要总结
This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has a confirmed clinical diagnosis of LGS with a history of seizures and actively experiencing seizures within 6 months of screening.
- •Is naïve to CBD-OS treatment or has been off CBD-OS treatment for at least 3 months prior to screening.
- •Is willing to maintain any factors expected to affect seizures (eg, alcohol consumption, smoking, concomitant medication usage) stable for the duration of the study.
- •Is currently treated with at least 1 ASM, but no more than 3 ASMs, and is on a stable regimen for at least 4 weeks prior to screening.
- •Adequate contraceptive precautions
- •Participant has a primary caregiver/legally authorized representative (LAR) who is willing and able, in the investigator's opinion, to participate throughout the duration of the study and to comply with all study requirements
- •Experienced at least 4 or more countable major motor seizures (isolated seizures or seizures occurring in a cluster) during the 5-week Baseline Period preceding treatment.
- •Caregiver completed at least 80% of seizure diary entries during the Baseline Period with no more than 3 consecutive days of missing entries.
排除标准
- •Has a significant psychiatric illness
- •Has an illness during the 4 weeks prior to screening other than epilepsy which, in the investigator's opinion, could affect study outcomes or seizure frequency.
- •Has history of SE in the 3 months prior to screening.
- •Has any other significant disease other than epilepsy, which, in the investigator's opinion, may either put the participant, other participants, or site staff at risk because of participation in the study, may influence the result of the study, or may affect the participant's ability to take part in the study.
- •Has previously undergone significant surgery for epilepsy in the 6 months prior to screening or planned to undergo surgery for epilepsy during the study.
- •Is currently using or has in the past used recreational or medicinal cannabis or synthetic cannabinoid-based medications, products, or supplements within the 3 months prior to screening and is not willing to undergo a 1-month washout period before being rescreened.
- •Has initiated felbamate within the 12 months prior to screening.
- •Is not willing to adjust dosage of CBD-OS if needed when using strong inducers of CYP3A4 and/or strong inducers of CYP2C19 concomitantly with CBD-OS
- •Previously discontinued cannabidiol due to severe adverse events (SAE), hypersensitivity or lack of efficacy
- •Has clinically significant abnormal lab values
- •Has clinically impaired hepatic or renal function
- •History of, current risk or presence of actual suicidal ideations
- •Has any known or suspected hypersensitivity to cannabinoids or any of the excipients of CBD-OS, such as sesame oil.
- •Has a known or suspected history of alcohol or substance abuse disorder
- •Is currently consuming, and unwilling to stop consumption, or planning to consume tonic water on a regular basis throughout the study.
研究组 & 干预措施
Cannabidiol Oral Solution Treatment group
Experimental
Participants who will receive the Cannabidiol Oral Solution (CBD-OS) titrated up to a dose of 20 mg/kg per day or the maximum tolerated dose for 24 consecutive weeks.
干预措施: Cannabidiol Oral Solution (Drug)
结局指标
主要结局
Percentage of participants reporting 50% or more reduction in their 28-day average countable major motor seizure frequency
时间窗: End of Treatment Period, Week 24
次要结局
- Number of Participants with Abnormal Laboratory Values(Up to week 24)
- Retention Rate(At Weeks 8, 12, 16 and 24)
- Percentage of participants experiencing worsening, change, no change or improvement in in their 28-day average countable major motor and total seizure frequency(Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24)
- Percentage of participants considered treatment responders(Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24)
- Change in 28-day average frequency of countable major motor and total seizures(Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24)
- Change in number of seizure-free days(Baseline to Week 4, Baseline to Week 8, Baseline to Week 12, Baseline to Week 16, Baseline to Week 24)
- Change in CaGI-S severity of seizure scores(Baseline to Week 16, Baseline to Week 24)
- Change in CaGI-S severity of impact of seizures scores(Baseline to Week 16, Baseline to Week 24)
- Change in VAS scores(Baseline to Week 16, Baseline to Week 24)
- Change in CaGI-S severity of level of alertness scores(Baseline to Week 16, Baseline to Week 24)
- Change in CaGI-S severity of overall condition scores(Baseline to Week 16, Baseline to Week 24)
- CaGI-C level of alertness scores(At Week 16, at week 24)
- CaGI-C overall condition scores(At Week 16, at week 24)
- Change in CGI-S overall condition scores(Baseline to Week 16, Baseline to Week 24)
- CGI-C overall condition scores(At Week 16, At Week 24)
- Change in ELDQOL Behavior subscale scores(Baseline to Week 16, Baseline to Week 24)
- Change in suicidal ideation scores(Baseline, up to week 24)
- Change in ELDQOL seizure severity subscale scores(Baseline to Week 16, Baseline to Week 24)
- Change in ELDQOL mood scale subscale scores(Baseline to Week 16, Baseline to Week 24)
- Change in ELDQOL side-effects profile subscale scores(Baseline to Week 16, Baseline to Week 24)
- Number of participants reporting adverse events leading to discontinuation(Up to week 24)
- Time the adverse events started from baseline(Up to week 24)
- Change in number of suicide attempts(Baseline, up to week 24)
- Percentage of participants requiring inpatient hospitalization due to epilepsy(Up to week 24)
- Change in number of usage of rescue medication(Baseline, Up to week 24)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
3 期
A clinical study to check efficacy and safety of Envafolimab injection in treatment of lung cancer.Malignant neoplasm of overlappingsites of bronchus and lung,CTRI/2025/09/094871Glenmark Specialty SA180
招募中
3 期
Phase III study to determine Efficacy, Safety and Tolerability of Oral Nafithromycin in comparison with Oral Amoxicillin-Clavulanic Acid and Azithromycin in adult participants with Acute Bacterial RhinoSinusitis (ABRS)Acute sinusitis, unspecified,CTRI/2025/12/099360Ms Wockhardt Limited290
尚未招募
3 期
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.Colorectal CancerNCT07595276Taizhou Mabtech Pharmaceutical Co.,Ltd608
招募中
4 期
To evaluate the Safety and Efficacy of Tislelizumab in Esophageal and Lung CancerMalignant neoplasm of esophagus, unspecified, (2) ICD-10 Condition: C349||Malignant neoplasm of unspecifiedpart of bronchus or lung,CTRI/2026/04/107830Glenmark Pharmaceuticals Ltd90
招募中
3 期
Randomized, multicenter, double-blind, Phase 3 study investigating the safety and efficacy of dostarlimab plus belrestotug compared with pembrolizumab plus placebo in participants with previously untreated, unresectable, locally advanced or metastatic Non-small-cell lung cancerMalignant neoplasm of unspecifiedpart of bronchus or lung,CTRI/2024/10/075244GlaxoSmithKline1,000